ADHERIUM LIMITED — Director's Dealing 2018

Mar 11, 2018

==> picture [121 x 33] intentionally omitted <==

Adherium’s Directors Purchase Approximately 1.4 Million Shares on the Open Market

San Mateo, CA - March 12, 2018: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, today announced that members of its Board of Directors recently purchased approximately 1.4 million shares on the open market. The timing of these purchases complied with the Company’s “blackout period” policy that required directors and employees to wait seven days following public disclosure of Adherium’s first half 2018 financial results.

“I’m delighted to see this level of support from our Board members. Their personal investment at this time demonstrates a commitment to the Company, as well as confidence in our strategy,” said Arik Anderson, CEO. “We had a great start to fiscal 2018, with first half results that included a 92% increase in revenue and a 63% increase in delivered devices over the comparable period in 2017, demonstrating the meaningful traction we are gaining.”

About Adherium

Adherium is a provider of digital health solutions and a global leader in connected respiratory medical devices. The Company develops, manufactures and supplies patients, pharmaceutical companies, healthcare providers and contract research organizations with the broadest range of connected medical devices for respiratory medications to address sub-optimal medication use and improve health outcomes in chronic disease. Adherium is headquartered in the USA, and operates globally from bases in the USA, Europe and Australasia. Learn more at www.adherium.com.

Inquiries

Vik Panda, Adherium Email: vikp@adherium.com

Media

Chris Gale, Greentarget Phone: 646.695.2883 Email: cgale@greentarget.com

Investors

Leigh Salvo, Gilmartin Group Phone: 415.937.5404 Email: leigh@gilmartinir.com